Check Your Claims Before Reviewers Do

 Quick Explanation Copied

 Long Explanation

Author Review: Stefano Volinia

Stefano Volinia presents a three-decade career spanning signal-transduction structural biology (14-3-3 phosphopeptide binding, Cell 1997) to becoming a founding contributor of cancer microRNA genomics OpenAlex career metrics and top works. The supplied evidence records show why his citation profile is exceptional: the 2006 PNAS miRnome analysis of 540 tumor samples across six cancer types defined a miRNA expression signature of solid tumors and remains his most cited work (~5,690 citations), while collaborative miRNA signature papers in breast, thyroid, ovarian, and pancreatic cancer each exceeded 1,100 citations Landmark miRNA signature papers.

Recent empirical strength (2026 CTCeek study). The February 2026 preprint integrates 3,302 putative CTCs from 27 public GEO/SRA datasets, retains 1,230 after QC, removes 900 contaminants, and validates CTCeek on 136 cells, achieving 99.96% specificity on pbmc3k (0.037% FPR) and 99.99% on 44,433 Broad PBMCs, with open data (Zenodo) and code (GitHub) — strong reproducibility practices and honest reporting of six misclassified aneuploid cells (4 HSPCs, 2 platelets) CTCeek single-cell CTC profiling preprint. However, the authors transparently note that most CTC data are EPCAM-selected, breast dominates (1,060 of 1,230 QC-passed cells vs. 6 colorectal, 2 lung), and external validation across diverse cancers is still needed Dataset composition and bias disclosures. A pending US patent (US 18/811,711) on this work is a declared financial interest Declared patent and funding COI.

Mechanistic depth (2011 miR-155 mutator study). The PNAS 2011 paper shows miR-155 overexpression (up to 32.07-fold in MDA-MB-231 clones) and inflammatory stimuli raise mutation rates (2.52-fold with TNF/LPS, P = 0.038; 2.81-fold in HCT116) via WEE1 checkpoint downregulation, using Luria-Delbrück fluctuation analysis across multiple cell lines and Eμ-miR-155 mouse B cells miR-155 mutator phenotype paper. Stated limitations include supra-physiological Tet-On overexpression, LSMCM being a complex inflammatory mixture, and reliance on HPRT as a surrogate for genome-wide mutation Reported limitations of miR-155 study.

The log-scale trajectory shows a massive citation half-life anchored to the 2005-2009 microRNA era, a long plateau of durable influence, and near-zero citations for the 132 works produced in 2023 — an anomalous productivity spike whose impact is not yet visible and cannot be evaluated from these data alone Citation trajectory and 2023 output anomaly.

What would change this assessment: independent failure of CTCeek's markers on external non-breast cohorts, non-replication of the miR-155 mutator effect at physiological miR-155 levels, or evidence linking the 2023 output spike to low-quality venues would lower the evaluation; conversely, prospective validation of CTCeek markers across cancer types would confirm the recent-direction strength. Uncertainty: the CTCeek paper is a 2026 preprint with zero incoming citations and unverified peer review CTCeek preprint provenance. Explore Volinia's Citation Network Check miR-155 Replication Evidence

 BGPT Author Review

Scientific Quality

H-index 91 with 57,470 citations reflects field-defining contributions: the 2006 solid-tumor miRnome paper and the 2005 CLL/NEJM prognostic signature papers are foundational to cancer miRNA genomics. Early structural biology (14-3-3, Cell 1997) shows breadth beyond one field. Recent CTCeek work demonstrates modern single-cell computational competence with strong open-data practices. Deductions: the 132-works-in-2023 anomaly with only 34 citations is a red flag for output quality or venue selection that the data cannot resolve; the 2011 miR-155 mutator study has reproducibility limitations (supraphysiological overexpression, HPRT surrogate); no primary-lab wet-lab leadership is evident in the recent computational work.

Communication Quality

Papers show clear quantitative reporting with explicit limitation sections, declared COIs, falsification criteria, and accessible tool delivery (Shiny app, GitHub, Zenodo). However, as a co-author on many large consortium papers, first-person scientific communication and standalone writing clarity are hard to judge; the CTCeek paper's dense multi-tool methodology may challenge non-specialist readers.

Author Novelty

The 2005-2007 miRNA signature papers were genuinely groundbreaking at the dawn of cancer miRNA genomics, establishing expression signatures across solid tumors and linking miR-15/16 to BCL2. The 2011 miR-155 mutator mechanism linking inflammation to genome instability via WEE1 was conceptually novel. The 2026 CTCeek work is incremental-but-novel: pan-CTC markers beyond EPCAM and a contaminant-aware classifier fill a real gap, though it is a tool/aggregation paper rather than a conceptual advance.

Scientific Rigor

Strengths: Luria-Delbrück fluctuation analysis with multiple clones and cell lines in the 2011 study; multi-tool QC pipeline (CopyKAT, SCEVAN, scATOMIC, doublet detection) with explicit misclassification reporting in CTCeek; data and code openly deposited. Weaknesses: supra-physiological Tet-On overexpression confounds physiological inference; HPRT is a narrow mutational surrogate; LSMCM is an ill-defined inflammatory mixture; CTC datasets are EPCAM/breast-skewed, limiting marker generality; CTCeek lacks independent external validation; the 2023 output spike raises unresolvable venue-quality questions.